Generalized anxiety disorder and irritable bowel syndrome

A. Ford

DOI: https://doi.org/10.1111/j.1365-2036.2009.04127.x

2009-11-01

Abstract:Generalized anxiety disorder and irritable bowel syndrome SIRS, I read the article by Lee et al. with interest. In their cross-sectional survey, conducted among the general population of Hong Kong, they reported that irritable bowel syndrome (IBS) is strongly associated with generalized anxiety disorder. The results of this study are interesting and important, with an adjusted odds ratio for generalized anxiety disorder in IBS of almost six. However, despite the fact that the study was conducted in over 2000 individuals, the absolute numbers of individuals involved in this subgroup analysis were relatively small (only 18 of 109 individuals with IBS met criteria for generalized anxiety disorder) and the confidence intervals were wide, presumably because of the relatively low prevalence of IBS in their population. In addition, the accuracy of the criteria used to define generalized anxiety disorder, as assessed over the telephone, are not reported in full. As the authors correctly pointed out in their discussion, because of its cross-sectional nature, the study cannot provide further information about any temporal association between IBS and generalized anxiety disorder. They suggested that co-existent IBS and generalized anxiety disorder may benefit from treatment with selective serotonin reuptake inhibitors (SSRIs). Whilst randomized controlled trials (RCTs) examining the efficacy of SSRIs in IBS have demonstrated conflicting results, a recent systematic review and meta-analysis has shown that they are of benefit with a number needed to treat to prevent one patient’s symptoms persisting of 3.5. However, as the majority of eligible RCTs included in this meta-analysis did not collect anxiety and depression data as part of their design, it is difficult to know whether the beneficial effects of SSRIs on IBS symptoms are exerted independently of any improvement in coexistent anxiety or depression. In the future, we need prospective cohort studies to examine the relationship between anxiety and depression and IBS further. We also need large welldesigned RCTs examining the efficacy of SSRIs and other antidepressants in IBS that, as one of their outcomes of interest, assess how much of their therapeutic efficacy is because of the successful treatment of co-existent anxiety or depression.